Patents by Inventor Srinivasa Karra

Srinivasa Karra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS
    Publication number: 20240101539
    Abstract: Extracellular protein degraders and compositions are provided that have a potent asialoglycoprotein receptor (ASGPR) Binding Ligand bound to an Extracellular Protein Targeting Ligand for the selective degradation of the Target Extracellular Protein, for example immunoglobulin in vivo to treat disorders mediated by the extracellular protein.
    Type: Application
    Filed: July 11, 2023
    Publication date: March 28, 2024
    Applicant: Avilar Therapeutics, Inc.
    Inventors: Jason Allan Wiles, Srinivasa Karra, Mark George Saulnier, Jesse Jingyang Chen, Kevin Tyler Sprott, Soumya Ray
  • Substituted Piperidino Compounds and Related Methods of Treatment
    Publication number: 20240076283
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: August 4, 2023
    Publication date: March 7, 2024
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Brian Kenneth Raymer, Jörg Martin Bentzien, Jonathan Ward Lehmann, Srinivasa Karra, Roman A. Valiulin, Daljit Matharu
  • ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
    Publication number: 20240072809
    Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.
    Type: Application
    Filed: July 11, 2023
    Publication date: February 29, 2024
    Applicant: Avilar Therapeutics, Inc.
    Inventors: Mark George Saulnier, Jesse Jingyang Chen, Srinivasa Karra, Kevin Tyler Sprott, Jason Allan Wiles, Soumya Ray
  • ASGPR-binding compounds for the degradation of extracellular proteins
    Patent number: 11819551
    Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: November 21, 2023
    Assignee: Avilar Therapeutics, Inc.
    Inventors: Mark George Saulnier, Jesse Jingyang Chen, Srinivasa Karra, Kevin Tyler Sprott, Jason Allan Wiles, Soumya Ray
  • SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT
    Publication number: 20230339969
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 26, 2023
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Roman A. Valiulin, Brian Kenneth Raymer, Jörg Martin Bentzien, Michael R. Hale, Jonathan Ward Lehmann, Daljit Matharu, Srinivasa Karra
  • Substituted piperidino compounds and related methods of treatment
    Patent number: 11760747
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: September 19, 2023
    Assignee: Alkermes, Inc.
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Brian Kenneth Raymer, Jörg Martin Bentzien, Jonathan Ward Lehmann, Srinivasa Karra, Roman A. Valiulin, Daljit Matharu
  • ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS
    Publication number: 20230097256
    Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.
    Type: Application
    Filed: July 29, 2022
    Publication date: March 30, 2023
    Applicant: Avilar Therapeutics, Inc.
    Inventors: Mark George Saulnier, Jesse Jingyang Chen, Srinivasa Karra, Kevin Tyler Sprott, Jason Allan Wiles, Soumya Ray
  • Substituted macrocyclic compounds and related methods of treatment
    Patent number: 11542276
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: January 3, 2023
    Assignee: Alkermes, Inc.
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Roman A. Valiulin, Brian Kenneth Raymer, Jörg Martin Bentzien, Michael R. Hale, Jonathan Ward Lehmann, Daljit Matharu, Srinivasa Karra
  • Substituted Macrocyclic Compounds and Related Methods of Treatment
    Publication number: 20220194958
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 23, 2022
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Brian Kenneth Raymer, Jörg Martin Bentzien, Jonathan Ward Lehmann, Michael R. Hale, Srinivasa Karra, Roman A. Valiulin, Daljit Matharu
  • SUBSTITUTED PIPERIDINO COMPOUNDS AND RELATED METHODS OF TREATMENT
    Publication number: 20220194926
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 23, 2022
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan HU, James R. Woods, Brian Kenneth Raymer, Jörg Martin Bentzien, Jonathan Ward Lehmann, Srinivasa Karra, Roman A. Valiulin, Daljit Matharu
  • Substituted Macrocyclic Compounds and Related Methods of Treatment
    Publication number: 20210155636
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 27, 2021
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Mugge, Yuan HU, James R. Woods, Roman A. Valiulin, Brian Kenneth Raymer, Jorg Martin Bentzien, Michael R. Hale, Jonathan Ward Lehmann, Daljit Matharu, Srinivasa Karra
  • TBK/IKK inhibitor compounds and uses thereof
    Patent number: 10428080
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: October 1, 2019
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Srinivasa Karra, Yufang Xiao
  • TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
    Publication number: 20180244682
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Application
    Filed: April 26, 2018
    Publication date: August 30, 2018
    Inventors: Brian A. SHERER, Srinivasa KARRA, Yufang XIAO
  • TBK/IKK inhibitor compounds and uses thereof
    Patent number: 9988391
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: June 5, 2018
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Srinivasa Karra, Yufang Xiao
  • TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
    Publication number: 20160376283
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKK? inhibitors.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 29, 2016
    Inventors: Brian A. SHERER, Srinivasa KARRA, Yufang XIAO
  • Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors
    Patent number: 8076486
    Abstract: The invention provides novel heteroaryl-substituted arylaminopyridine derivative MEK inhibitors of Formula (Ia) Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: December 13, 2011
    Assignee: Merck Serono S.A.
    Inventors: Andreas Goutopoulos, Benny C. Askew, Jr., Xiaoling Chen, Srinivasa Karra, Henry Yu
  • NOVEL ARYLAMINO N-HETERARYL COMPOUNDS AS MEK INHIBITORS
    Publication number: 20100256149
    Abstract: The invention provides novel arylamino N-heteroaryl MEK inhibitors of Formula (I): Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: June 14, 2010
    Publication date: October 7, 2010
    Applicant: MERCK SERONO S.A.
    Inventors: Andreas Goutopoulos, Benny C. Askew, JR., Nhut Kiet Diep, Srinivasa Karra, Matthias Schwarz, Henry Yu
  • Arylamino N-heteroaryl compounds as MEK inhibitors
    Patent number: 7772233
    Abstract: The invention provides novel arylamino N-heteroaryl MEK inhibitors of Formula (I): Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: August 10, 2010
    Assignee: Merck Serono, S.A.
    Inventors: Andreas Goutopoulos, Benny C. Askew, Jr., Nhut Kiet Diep, Srinivasa Karra, Matthias Schwarz, Henry Yu
  • Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors
    Publication number: 20070287737
    Abstract: The invention provides novel heteroaryl-substituted arylaminopyridine derivative MEK inhibitors of Formula (Ia) Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: April 18, 2007
    Publication date: December 13, 2007
    Inventors: Andreas Goutopoulos, Benny Askew, Xiaoling Chen, Srinivasa Karra, Yufang Xiao, Henry Yu
  • Novel arylamino N-heteraryls as MEK inhibitors
    Publication number: 20070287709
    Abstract: The invention provides novel arylamino N-heteroaryl MEK inhibitors of Formula (I): Such compounds are MEK inhibitors that are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation. Also disclosed is the treatment of a hyperproliferative disease in mammals, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: April 18, 2007
    Publication date: December 13, 2007
    Inventors: Andreas Goutopoulos, Benny Askew, Nhut Diep, Srinivasa Karra, Matthias Schwarz, Henry Yu